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Major facilitator superfamily domain containing 2a (MFSD2A) is a protein expressed by 
endothelial cells. It functions as a long chain fatty acid transporter, carrying fatty acids in the 
chemical form of lysophosphaditylcholine (LPC). It has recently been discovered that MFSD2A 
is the lipid transporter that carries docosahexaenoic acid (DHA) across the blood brain barrier 
into the brain. A role for MFSD2A in innate and adaptive T cells remains unclear. This is 
important to public health relevance because an understanding of how lipids are taken up and 
used during an activated effector T cell response is critical to fighting infection, immune disease, 
and even cancer. A search of the Immunological Genome Project (IMMGEN) Database reveals 
MFSD2A is upregulated in activated CD8 effector T cells exposed to Listeria monocytogenes, 
peaking at 12 hours post infection and decreasing over 48 hours. Preliminary microarray results 
of invariant natural killer T cells (iNKT), a form of innate cell, shows high upregulation of 
MFSD2A transcript upon in vitro activation with alpha-galactosylceramide. Results were 
validated using a real-time PCR approach in both activated iNKT and CD8 T cells. This was 
further supported by probing for MFSD2A protein analysis via western blot. In vitro activation 
studies using isolated CD8 T cells from C57BL/6 mice further support results by showing 
increased MFSD2A and LPC by flow cytometry analysis. Finally, a working in vivo congenic 
CD45.1 OT-I mouse infection model of Listeria monocytogenes tagged to OVA-peptide 
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recapitulates IMMGEN findings as MFSD2A is higher expressed at 12-72 hours post infection 
compared to wildtype OT-I control mice. These data all support the claim that MFSD2A and 
LPC play a critical role for lipid metabolism within the innate and adaptive effector T cell. 
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1.0  BACKGROUND AND SIGNIFICANCE 
1.1 INTRODUCTION TO EFFECTOR T CELLS 
     The immune system is composed of both fast-acting innate cells and delayed long-
lasting adaptive cells that work together to keep the host free of pathogen. One innate cell 
type that helps to bridge the gap between innate and adaptive immune systems is the 
invariant natural killer T cell (iNKT). NKT cells undergo thymic development like other T 
cells but branch off at the double positive stage into a committed NKT lineage [1]. NKTs 
respond quickly to an immune response by using a semi-invariant CD1d-restricted T cell 
receptor (TCR); enabling rapid cytokine production and creating a memory-like NKT 
phenotype  [1, 2]. Unlike traditional CD4 or CD8 T cells, NKT cells respond to lipid antigen. 
The first and most common NKT cell ligand originated from the marine sponge Agelas 
mauritianus [2]. It was found to be directly caused by alpha-branched galactosylceramide, 
now commonly referred to as aGalCer. Since their discovery, numerous subsets of NKT 
cells have constantly been discovered with a lineage based off of transcription factor 
differentiation and cytokine production [2]. Taking advantage of their unique and rapid 
effector phenotype, the potential use of NKT cells as cancer or autoimmune therapy is 
a continuously growing field. Figure 1 below shows the extensive differentiation of NKT 
cells, including their origin from double positive CD4 CD8 T cells that will be discussed 
below. 
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Figure 1. NKT and CD4 CD8 T cell selection in the thymus 
(adapted from Godfrey et al. ) 
CD8 effector T cells also undergo thymic development (see above). CD8 T cells, unlike 
NKT cells, bind to glycoproteins bound to major histocompatibility complex I (MHC I), a 
surface receptor found on all nucleated cells [3, 4]. In order to become active, they require two 
stimuli. The first being the cell’s TCR binding to MHC I. The second stimulus is the co-stimulus 
surface receptor CD28 on the T cell binding to CD80 CD86, however this can be enhanced or 
replaced by certain cytokines [5]. This usually occurs by means of an antigen presenting cell 
(APC), normally a dendritic cell in this case.  One example of this is OVA-albumin peptide 
binding to the MHC I receptor on an APC and being presented to the TCR of the CD8 T cell, 
initiating an adaptive immune response and cytotoxic activities of the T cell. 
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1.2 EFFECTOR T CELL RESPONSE TO INFECTION IN MOUSE AND HUMAN 
      Upon infection, effector T cells undergo a transition from a quiescent, poor effector 
state, to metabolically active, proliferating cells that have the ability to produce cytokines 
rapidly[4, 5]. With such a large change in cellular state, it may not be surprising that this is 
accompanied by changes in gene expression at each stage of differentiation. Different 
pathogens can create different innate immune responses that go on to create an adaptive 
immune response that is infection-specific [4, 6]. Many of these signaling pathways are hot 
targets for vaccines and cancer therapy. 
1.3 T CELLLIPIDOMICS AND METABOLISM 
Naive T cells undergo major metabolic changes upon activation, infection, and cancer. 
Unactivated T cells are in a relatively quiescent state and predominately use oxidative 
phosphorylation (OXPHOS) as their metabolic means, whereas effector T cells primarily use 
glycolysis. A portion of these effector cells will differentiate into memory T cells that use both 
OXPHOS and lipolysis to fulfill energy requirements [6, 7]. This metabolic shift combined with 
increased energy demands for effector T cells indicates a need for diet and nutrition to properly 
generate an immune response. Research on the effector T cell immune response almost 
exclusively focuses on how these cells use metabolites to increase or decrease energy production 
[6-8]. Recent studies have focused on how activated effector T cells incorporate exogenous 
glycerol and glucose fuel sources to the synthesis of triacylglycerides and ATP [9, 10]. It is 
known that activated effector T cells can take up exogenous long chain fatty acids (LCFAs) from 
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their environment to assist with energy production [11]. There is, however, no knowledge on 
how effector T cells transport phospholipids such as lysophosphatidylcholine (LPC) and LCFAs 
across cellular membranes and what is regulating this process. This represents a huge gap in the 
understanding of effector T cell metabolism, especially in relation to how they use LCFAs to 
illicit an immune response.  
1.4 INTRODUCTION TO LPC AND MFSD2A 
LPC is a product of lysophospholipid (LPL) metabolism that is critical for maintaining 
cellular homeostasis with added therapeutic benefits such as wound healing and both 
autoimmunity and neurodegenerative treatment [12]. It is derived from polar surface 
phosphatidylcholine (PC) of lipoproteins or from cell membrane PC via phospholipase A2 [13]. 
It can be either directly formed from the liver or by altering low-density lipoprotein (LDL) 
cholesterol in vitro. LPC consists of one hydrophobic fatty acyl chain and one hydrophilic polar 
choline group attached to a glycerol backbone. LPC acts as the chemical transporter of many 
species of fatty acids between cells, making it an important component to cellular metabolism. 
One such fatty acid is docosahexaenoic acid (DHA). In order to perform these actions, LPC 
requires a carrier molecule. This carrier molecule is Major Facilitator Superfamily Domain 
Containing 2a (MFSD2A). 
MFSD2A is a 12 domain transmembrane protein. It has a well-established role as a lipid 
transporter that bears a close resemblance to the bacterial Na+/melibiose supporter [14-16]. 
Spanning 14 exons and 7.7 kb, it is conserved through vertebrate evolution and has a wide tissue 
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distribution in mouse with highest expression levels in kidney with cellular localization at the 
rough endoplasmic reticulum (ER) [14, 17, 18]. 
It was first discovered as a fasting-induced gene that regulated PPARa and glucagon in 
the liver and brown adipose tissue (BAT), suggesting its role in lipid metabolism, growth, and 
thermogenesis [16, 17]. MFSD2A was subsequently found to be an important sodium-dependent 
tucinamycin transporter in humans and if knocked out in human cell lines, tunicamycin uptake 
would be significantly decreased [18]. This experiment supported MFSD2A’s importance at the 
ER and role in cellular stress response. More recently, MFSD2A has been implicated in brain 
development and its important role as lipid transporter of DHA in the form of LPC across the 
blood brain barrier (BBB) [15, 19]. 
 
Figure 2. Biochemical metabolism of LPC 
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1.5 MFSD2A AND ITS RELATION TO DHA AND THE BRAIN 
DHA has been well documented for its critical role in brain development [20-22]. It is 
essential for normal brain growth and cognition. However, since the brain cannot synthesis DHA 
de novo, the mechanism of how it crossed the BBB was unknown until recently. In 2014, 
MFSD2A was found to be the major transporter of DHA across the BBB into brain endothelium, 
and it does so by transporting DHA in the form of LPC in a sodium- dependent manner [15]. 
 
Figure 3. MFSD2A/DHA interaction of BBB 
1.6 MFSD2A, IMMUNOLOGY, AND PUBLIC HEALTH 
The mechanism by which effector T cells take up LCFAs and how it is regulated is still 
unknown. The potential role of MFSD2A as the carrier molecule of fatty acids into activated T 
cells by means of chemical form LPC would be a huge breakthrough in understand of  effector T 
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cell metabolism. Activated T cells require higher energy demands to properly initiate an immune 
response, to clear infection or tumors. Elucidating this pathway is very important to public 
health, as these metabolic instruments hold potential therapeutic benefits to patients. The World 
Health Organization (WHO) and American Heart Association both recognize DHA as an 
important component to a healthy lifestyle. The research herein signifies an urgent need to 
understand and target how phospholipids, LCFAs, and DHA are imported into the effector T cell 
and how they impact the immune response to infection 
1.7 OBJECTIVES 
The main objective of this project is to uncover the role of MFSD2A in innate and 
adaptive effector T cell response. This has been accomplished using a multi-discipline approach 
of combining techniques including a literature review, molecular techniques, flow cytometry, 
and in vitro and in vivo mouse models under naïve and activated states. The following goals are 
used to determine the main objective: 
1. Candidate gene studies on potential lipid transporter and effector T cell genes 
2. A literature review for background on MFSD2A genotype and phenotype data 
3. Molecular validation of MFSD2A results found in 1 
4. In vitro activation analysis of MFSD2A in wildtype mouse 




The above goals are well illustrated in the figure below. The main objective of this project is to 
prove that MFSD2A with LPC are the means that effector T cells receive an influx of lipids upon 
activation and can then help to induce downstream effects to clear infection or tumors. A visual 
summary of experiments is summarized in the APPENDIX D flow chart. 
 
 
Figure 4. Proposed role of MFSD2A and LPC in activated effector T cell 
 
Figure is shown relative to the known mechanism of MFSD2A and LPC in the brain to allow 




2.0  MATERIALS AND METHODS 
2.1 MICROARRAY OF NKT TARGETS 
A MoGene 1.0 mouse exon microarray chip (Affymetrix) was used to compare activated 
versus naïve NKT cells at 3 hours, 3 days, and 6 days. Cells from wildtype C57BL/6 mice (The 
Jackson Laboratory) were activated in vivo with aGC at 2 ug/mL.  
2.2 DATABASE MINING OF MICROARRAY HITS 
Top hits for fold-increase or decrease from microarray results from naïve NKT and 3 
hour or 3 day activated NKT cells were further investigated by using the ImmGen database, a 
project of the Immunological Genome Project that can be found at www.immgen.org. A data 
browser search was performed using the Gene Skyline method to measure expression profile 
across a panel of immunologically relevant cell types and conditions. Specifically, activated T 
cells were searched for MFSD2A.  
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2.3 MFSD2A GENOTYPE AND PHENOTYPE LITERATURE SEARCH 
MFSD2A was searched in both PubMed and OMIM databases. Almost all known data is 
exclusively related to brain function, development, and BBB.  A database search of “MFSD2A 
and immunology” or “MFSD2A and T cells” contained no results.  
2.4 NKT AND CD8 T CELL HARVESTING AND REAL-TIME PCR VALIDATION 
Six 6-8 week old wild-type C57BL/6 mice were activated in vivo with either 2uM alpha-
galactosylceramide or PBS for three hours then sacrificed. Spleen was harvested in PBS 2% 
FCS. Lymphocytes were extracted, pelleted, and counted. 20 million cells were stained for TCRb 
and CD1d-tetramer using antibodies from eBioscience and NIH Core Tetramer Facility at Emory 
University, respectively. iNKT cells were gated and collected on TCRb+ CD1d-tet+ using a BD 
FACS Aria cell sorter at the Flow Cytometry Core of the University of Pittsburgh. iNKT cells 
were sorted in Trizol (Invitrogen) and frozen at -80C until RNA extraction.  
For CD8 T cells, 6-8 week old C57BL/6 mice were sacrificed and spleens harvested in 
PBS 2% FCS. Lymphocytes were extracted and counted. CD8 T cells were enriched using 
biotinylated CD8a antibody (eBioscience) and streptavidin-conjugated microbeads (Miltenyi 
Biotech, Inc.). CD8 T cells were counted and plated at 2x106 cells/well in T cell media (RPMI, 
10% FBS, 2% of each l-glutamine and pen-strep). Prior to plating, a 96 well plate was coated in 
anti-CD3 (eBioscience) for a minimum of 2 hours at 37C. Activated cells were cultured in wells 
coated with anti-CD3 and co-cultured with anti-CD28 (eBioscience) for 24, 48, and 72 hours. 
Cells were pelleted, resuspended in Trizol, and frozen at -80 until RNA extraction. Frozen Trizol 
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samples were thawed on ice. RNA was extracted using the Trizol Extraction Protocol For Sorted 
Cells found on the ImmGen database 
(https://www.immgen.org/Protocols/Total%20RNA%20Extraction%20with%20Trizol.pdf). 
Reverse transcription was performed using the All-in-One First Strand cDNA synthesis kit from 
Genecopoeia. Genomic DNA was removed using the DNA-free Removal Kit (Invitrogen). Real-
time PCR was performed using the All-in-One qPCR kit (Genecopoeia) and a Roche 
LightCycler 96 SYBR Green analysis. Primers for MFSD2A were designed using a combination 
of NCBI Primer-BLAST and Primer Bank from Harvard University.  
2.5 WESTERN BLOT FOR MFSD2A 
Sample prep for CD8 T cells is the same as listed above. Cells were pelleted after 24, 48, 
and 72 hours of in vitro activation. Cells were incubated at 95C in SDS buffer containing b-
mercaptoethanol for 5 minutes prior to Western blotting. Samples were ran on a 5-20% gradient 
gel (Bio-Rad) and transferred onto PVDF membrane on ice. Primary antibody for MFSD2A 
conjugated to anti-rabbit was purchased from Abcam. Membranes were visualized on Protein 
Simple FlouroChem machine (Biotechne). Quantification studies were performed using ImageJ 
software (NIH). 
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2.6 IN VITRO ANALYSIS FOR MFSD2A AND LPC 
CD8 T cells were harvested as described above and stimulated with anti-CD3 anti-CD28 
for 24, 48, and 72 hours. For each given timepoint, cells were co-cultured with TopFluor LPC 
(Avanti Polar Lipids) at 0.1uM. Cells were pelleted and stained for viability using Zombie Aqua 
viability dye (BioLegend). Cells were next surface stained for flow cytometry analysis using 
antibodies for CD8a, CD44, and CD62L (eBioscience). Cells were fixed and permeabilized  
using Cytofix/Cytoperm buffer kit (BD Biosciences). Permeabilized cells were stained with anti-
MFSD2A (Abcam) conjugated to anti-rabbit PE to visualize. Stimulated CD8s were compared to 
naïve controls. TF-LPC is represented as GFP. 
2.7 IN VIVO ANALYSIS FOR MFSD2A 
The in vivo approach makes use of an adoptive transfer model distinguishable by CD45 
common leukocyte antigen and OT-I transgenic CD8 T cells. The reasoning for using OT-I mice 
is that the transgenic Va2 Vb5 TCR is designed to recognize ovalbumin residues to study the role 
of peptides in the T cell’s response to antigen. Mice naively express almost exclusive CD8+ 
MHC I T cells with a very low population of CD4+ MHC II T cells. The percent of CD8+ cells 
that express Va2 Vb5 TCR is roughly 20%.  
1x106 transgenic OT-I Va2 CD8 T cells were adoptively transferred retrorbitally into 
congenically labeled CD45.1 C57BL/6 mice. On the following day, mice were injected IV with 
5000 CFU listeria-OVA. Mice were bled from the submandibular vein at 1, 2, 3, 5, and 7 days 
into PBS 0.5% EDTA. A diagram of this model is in Appendix C. Lymphocytes were isolated 
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from whole blood and analyzed by flow cytometry as described above. Additionally, mice were 
stained for KLRG1 and CD127 to track the state of infection (effector versus effector memory).  
The below figure is representative of FACS plots for typical infection timecourse. Total 
MFSD2A is measured directly from CD45.1-/CD8+/Va2+/CD45.2+ OT-I cells. 
 
 
Figure 5. In vivo model for MFSD2A FACS analysis 
 
The top of Fig. 5 is positive control naïve OT-I cells. Middle panel is day 3 early 
infection. Bottom panel is day 7 peak of infection. Gating schematic is as follows, going across: 
SSC FSC gate of total lymphocyte population from blood. Next, gate out CD45.1 recipient cells. 
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Then, gate on double positive CD8a Va2 cells. These are the donor OT-I cells. To confirm, 
regate this population on CD45.2 Va2 and it should be near 100% pure. 
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3.0  RESULTS 
3.1 MICROARRAY RESULTS 
Summarized results of top hits for genes upregulated in iNKT cells activated in vivo with 
2 ug/mL aGalCer. Most results contain genes with a known association with the immune system 
and where therefore not further pursued. 
 
Table 1. iNKT microrray results summary 
 
MFSD2A results highlighted in red. All genes normalized to GAPDH. 
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3.2 DATABASE MINING RESULTS 
Results from search of the ImmGen database for MFSD2A. Results are comparing 
transgenic OT-I CD8 T cells to naïve CD8 T cells for MFSD2A. This is an in vivo model of 
infection characterizing response to relative amount of OVA peptide tagged Listeria 
monocytogenes at given timepoints. Peak infection is represented at 8d. Memory timeframe is 
45d. Note that expression in naïve is near 60 fold. 
 
 
Figure 6. IMMGEN database results for MFSD2A 
Relative amount of MFSD2A in naïve versus in vivo activated OT-I CD8 T cells. 
Lm-OVA; Listeria monocytogenes. 
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3.3 MFSD2A GENOTYPING AND PHENOTYPING RESULTS 
NCBI’s PubMed biomedical database and OMIM (Online Mendelian Inheritance of Man) 
result in two hits, summarized in a total of three families with known MFSD2A point mutation 
syndromes. Families from Libya and Egypt suffer from a completely inactivating loss of 
MFSD2A, while the family from Pakistan has a partially inactivating loss of MFSD2A[14, 23]. 
Phenotypes are similar however a completely inactivating mutation results in lethality in 
childhood. All families studied were to some degree consanguineous with no other known 
mutations leading to phenotype. 
 
Table 2. MFSD2A phenotyping results 
 
3.4 REAL-TIME PCR RESULTS 
NKT and CD8 T activated effector cells were analyzed for Mfsd2a expression relative to 
naïve effector cells and normalized to GAPDH.  Cells were activated in vitro with anti-CD3 anti-
CD28. Each graph is representative of three triplicate studies, n=3 for each. 
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To validate the ImmGen data, cells were also activated in vivo using CD45.2 OT-I 
adoptive transfer lm-OVA model; n=1. 
 
 
Figure 9. Real-time PCR MFSD2A in vivo model in CD8 T cells 
3.5 WESTERN BLOTTING RESULTS 
Western blotting protein analysis for MFSD2A relative to BETA-ACTIN. CD8 effector T 




Figure 10. Western Blotting protein analysis of CD8 T cells 
Raw data (right) and quantified ratio of MFSD2A to BETA-ACTIN (left); n=1. 
3.6 IN VITRO RESULTS MFSD2A AND LPC 
CD8 T cells from wildtype C57BL/6 mice were activated in vitro as mentioned 
previously with LPC being added the last four hours of culture. Cells were analyzed by flow 
cytometry for MFSD2A PE and LPC GFP.  
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Figure 11. In vitro analysis of MFSD2A and LPC 
 
Top of figure is data relevant to MFSD2A. Far left is representative histogram of mean 
MFI for MFSD2A for 48 hour activated compared to naïve CD8 T cells. Middle FACS plot is 
comparing MFSD2A to CD44 activation marker, illustrating an increase in MFSD2A in parallel 
to activation. Far right panel is quantification of MFSD2A; p<0.0001 using Student’s T-test. 
Bottom half of the figure is for LPC GFP; analysis performed identically to MFSD2A; 
quantification p<0.0001 using Student’s T-test. Figure is representative of triplicate experiments 
with each experiment n=3. 
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3.7 IN VIVO RESULTS MFSD2A 
Below are representative flow cytometry FACS plots showing patterns of relative 
MFSD2A fluorescence intensity, comparing in vivo activated CD8 T OT-I transgenic mice that 
were adoptively transferred onto a congenic CD45.1 recipient that had been infected with 5000 




Figure 12. MFI for MFSD2A in vivo activated OT-I CD8 T cells from blood 
 
Next, to better classify the amount of MFSD2A early on in infection, infected spleens 
were harvested at 12, 24, and 48 hours post-infection to investigate MFSD2A fluorescent 
intensity. CD8 OT-I cells were analyzed based on effector or naïve status based on cell surface 




Figure 13. MFSD2A intensity of CD8 T cells in vivo from spleen 
Fluorescent intensity is highest in 12 hr CD44 hi CD62L lo effector CD8 T cells. Intensity decreases 
with time out to 72 hrs. 
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4.0  DISCUSSION 
Innate and adaptive effector T cells play a critical role in immunity, including clearance 
of infection and cancer, which makes finding out what makes them tick (i.e., metabolites, 
specifically lipidomics) very important in the hunt for cures and stepping up our bodies’ 
defenses. Herein, it is proposed that MFSD2A and LPC could provide the potential mechanism 
that makes it capable for effector T cells to increase metabolic output during activation and 
successfully clear the system of infection. MFSD2A is clearly upregulated in both iNKT and 
CD8 T, innate and adaptive effector T cells respectively, upon activation. This is shown by our 
microarray and real-time PCR validation as well as western blotting protein analysis. These data 
are further supported by in vitro culture of mouse splenic CD8 T cells that after activation, 
expressed significantly higher levels of both fluorescent MFSD2A and LPC. This is recapitulated 
in vivo by using lm-OVA as an infection/tracking model.   
There are a few potential pitfalls to the above approach. Protein levels seem to be highest 
at 72 hours, while mRNA levels peak around 12 hours, similar to the ImmGen data mentioned 
above. The delay in protein translation may be due to the time required for clonal expansion in 
order for the adaptive immune system to successfully illicit an immune response. Another area 
that needs to be addressed is repeating LPC flow cytometry measurements in the in vivo model. 
The reason this has not already been completed is because there is a lethality associated with I.V. 
LPC dosage and this problem has not been worked out as of print. Other gaps in the data include 
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lipidomic analysis for LPC GFP in activated and naïve effector T cell samples and LPC GFP 
microscopy work to complement the above data. Both of these missing links are being addressed 
and will be discussed in future endeavors. 
Preliminary real-time PCR and in vitro data using human peripheral blood lymphocytes 
(HPBL) has shown a promising translation from mouse data into a human model, as MFSD2A 
and LPC both are significantly higher in wildtype activated versus naïve human CD8 T cells 
(n=3) (data not shown). More human data is to be performed and expanded on in the near future, 
including western blotting protein analysis and repeating in vitro work. If these data hold true, it 
would make sense to move forward with an in vitro human MFSD2A  knock down model, such 
as shRNA technologies, to understand the effect on MFSD2A KD in humans. This would be of 
particular relevance for the families listed above with mutations in MFSD2A, as they may have a 
dysfunctional immune phenotype that has yet to be discovered. 
Another experiment to perform in the very near future will be to test the effect of 
MFSD2A deletion in CD4 T cells, using a cre-lox model of deletion. Using CD4-cre mice, 
MFSD2A will be deleted in all types of T cells during the double positive stage of thymic 
development. This will therefore also knock out MFSD2A in CD8+ and NKT cells. We 
hypothesis that upon KO, these mice will suffer a decreased effector T cell response during 
infection and that this KO will directly lead to a poorer prognosis for these mice. MFSD2A flox 
mice were kindly donated from the Silver Lab at Duke-NUS Singapore and are currently being 
bred on a CD4-cre OT-I background. 
Overall, accumulating data suggest that MFSD2A may be one of the missing links to 
understanding effector T cell metabolism during an immune response. Our data suggest this is 
true, but further experimentation needs to be performed, including in other model organisms, to 
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confirm that this is a real effect. Assuming data is conclusive, MFSD2A may be on the verge of 
becoming a critical player in effector T cell responses with an important role in general 






















APPENDIX A:  LIST OF REAL-TIME PCR PRIMERS 
 
 
Ccl3  TGTACCATGACACTCTGCAAC        CAACGATGAATTGGCGTGGAA 
Nr4a2  GTGTTCAGGCGCAGTATGG        TGGCAGTAATTTCAGTGTTGGT 
Cd24a  GGCTCTCTCTCTCTCTCTTCTAC       GGACTTGTGGTTGCCATTTG 
Cxcl9  AGAGTAGGGACCACAGACTATT      GCCTTTCTACCTCTCACACATAC 
Nr4a3  GCGCTGGTAGAACTGAGAAA        CAAGGAAGAGCTTGTCGATGA 
Nr4a1  GGCATGGTGAAGGAAGTTGTA        GGATGAGGGAAGTGAGAAGATTG 
Il2ra  GAGCCTGCCCAACTTTTTGTG        TGTAGTCCCCAACTCATCTGTG 
Egr3  CCGGTGACCATGAGCAGTTT        TAATGGGCTACCGAGTCGCT 
Sema7a ACACACCGTGCTTTTCCATGA        CCTTTGTGGAGCCGATGTTC 
IFNg  CGGCACAGTCATTGAAAGCCTA       GTTGCTGATGGCCTGATTGTC 







APPENDIX B:  LIST OF ANTIBODIES 
Antibody  Conjugate  Catalog #  Manufacturer 
CD45.2   BUV395  564616  BD Biosciences 
CD45.1   APC   17-0454-82  eBioscience 
CD8a    BV510   100752  BioLegend 
Vα2 TCR   BV421   48-5812-82  eBioscience 
CD44   PerCp-Cy5.5  45-0441-82  eBioscience 
CD62L   APC-Cy7  47-0629-42  eBioscience 
MFSD2A  -   ab105399  Abcam 
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